Expert KOL Webinar 21 June, page-7

I really enjoyed that presentation from James. Probably the mostinsightful presentation I’ve heard in some time. That’s bud @lonade

The things I’ve taken away from this interview 48.53. “we now looktowards the therapeutic window where efficacy exist which we would be extremelyconfident exists well below these dose parameters” I’m assuming that he’s referringto the data that we’ve already got from the IV clinical trials and the preclinical trials. So, I’m guessing Recce already have some idea that the windowexists below the 4000mg over an hour administration. Talking about the 4000mg administrationhe almost scoffs at the amount that’s being administered into the cohort (as ifmaybe its unnecessary).

So the 8000mg and 16000mg cohort is only to see where the compoundis no longer well tolerated and safe. (I know this has been already establishedin these forums)

The other thing that I took away form this interview is that R327MoA (Mechanism of Action) was identified by the same company that undertook thetesting for CUBIST pharmaceuticals and Vancomycin. It seems like thiswould put us within good company.

Vancomycin - is an antibiotic medication used to treat a number ofbacterial infections. It is recommended intravenously as a treatment forcomplicated skin infections, bloodstream infections, endocarditis, bone andjoint infections, and meningitis caused by methicillin-resistant Staphylococcusaureus

CUBIST pharmaceuticals – main compound (Daptomycin), sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms. In the United States, daptomycin is indicated for use in adults for skin and skin structure infections caused by Gram-positive infections, S. aureus bacteraemia

R327 has a multi layered mechanism of action “unlike that of anyantibiotic seen before” you’d have to think having a compound profile displayingnever before seen properties would be catching the eye of other pharmaceutical companies even at this early stage of clinical trials.

There are so many things to like about this company at the moment. Still a long way to go. very exciting times ahead. I think because people are so unaware about Sepsis its definitely kept our market cap as one of the best kept secrets on the ASX.
I found a document on the internet "Valuation and Returns of drug development company's: lesson for Bioentrepreneurs and investors. I've attached a snippet but it seems obvious that our market cap is still less than what I think it should be. Especially given the amount of positive announces from our $1.64 (14.9.2020) high.